Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic

Following onset of the first recorded case of Coronavirus disease 2019 (COVID-19) in December 2019, more than 269 million cases and over 5.3 million deaths have been confirmed worldwide. COVID-19 is a highly infectious pneumonia, caused by a novel virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, it poses a severe threat to human health across the globe, a trend that is likely to persist in the foreseeable future. This paper reviews SARS-CoV-2 immunity, the latest development of anti-SARS-CoV-2 drugs as well as exploring in detail, immune escape induced by SARS-CoV-2. We expect that the findings will provide a basis for COVID-19 prevention and treatment.

• Publication year

  2022

• Venue

  International Journal on Biological Sciences

• Publication date

  2022-02-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.7150/ijbs.66369PMID 35342348PMCID 8935217
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis

  2023cited by this paper
• Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

  2021cited by this paper
• Does the SARS-CoV-2 Spike Protein Receptor Binding Domain Interact Effectively with the DPP4 (CD26) Receptor? A Molecular Docking Study

  2021cited by this paper
• Innate immunity in COVID-19: Drivers of pathogenesis and potential therapeutic targets.

  2021cited by this paper
• Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19

  2021cited by this paper
• The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection

  2021influential reference
• Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19

  2021cited by this paper
• Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

  2021cited by this paper
• Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

  2021cited by this paper
• Type I Interferon Induction and Exhaustion during Viral Infection: Plasmacytoid Dendritic Cells and Emerging COVID-19 Findings

  2021cited by this paper
• Association of coagulation disturbances with severity of COVID-19: a longitudinal study

  2021cited by this paper
• Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19

  2021cited by this paper
• Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

  2021cited by this paper
• AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells

  2021cited by this paper
• Adaptive immunity to SARS-CoV-2 and COVID-19

  2021cited by this paper
• Potential therapeutic and pharmacological strategies for SARS-CoV2

  2021cited by this paper
• Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of Proteases beyond Furin

  2021cited by this paper
• Immune determinants of COVID-19 disease presentation and severity

  2021cited by this paper
• SARS-CoV-2 infection and thrombotic complications: a narrative review

  2021cited by this paper
• Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

  2021cited by this paper
• The Pathogenesis and Treatment of COVID-19: A System Review

  2021cited by this paper
• SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO

  2021cited by this paper
• Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection

  2021cited by this paper
• COVID-19 and the human innate immune system

  2021cited by this paper
• N-Acetylcysteine and Hydrogen Sulfide in Coronavirus Disease 2019

  2021cited by this paper
• Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials

  2021cited by this paper
• The ORF8 protein of SARS-CoV-2 induced endoplasmic reticulum stress and mediated immune evasion by antagonizing production of interferon beta

  2021cited by this paper
• The signal pathways and treatment of cytokine storm in COVID-19

  2021cited by this paper
• Low molecular weight heparin is useful in adult COVID-19 inpatients. Experience during the first Spanish wave: observational study

  2021cited by this paper
• Candidate drugs against SARS-CoV-2 and COVID-19

  2020cited by this paper
• Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids

  2020cited by this paper
• Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19

  2020cited by this paper
• An Update on Current Therapeutic Drugs Treating COVID-19

  2020cited by this paper
• A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection

  2020cited by this paper
• Early experience with remdesivir in SARS-CoV-2 pneumonia

  2020cited by this paper
• Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

  2020cited by this paper
• Renin–angiotensin–aldosterone system dysregulation and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection

  2020cited by this paper
• Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2

  2020cited by this paper
• Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

  2020cited by this paper
• SARS‐CoV‐2 infection‐induced immune responses: Friends or foes?

  2020cited by this paper
• Dysregulation of type I interferon responses in COVID-19

  2020cited by this paper
• SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

  2020cited by this paper
• Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

  2020cited by this paper
• COVID‐19 and renin‐angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) ‐ Is there any scientific evidence for controversy?

  2020cited by this paper
• Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID‐19

  2020influential reference
• Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site

  2020cited by this paper
• Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

  2020cited by this paper
• Anakinra for severe forms of COVID-19: a cohort study

  2020cited by this paper
• N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2

  2020cited by this paper
• Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients

  2020cited by this paper
• SARS-CoV-2 infection and stem cells: Interaction and intervention

  2020cited by this paper
• Mesenchymal Stem Cell-based Therapy for COVID-19: Possibility and Potential.

  2020cited by this paper
• COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.

  2020cited by this paper
• Clinical performance of different SARS‐CoV‐2 IgG antibody tests

  2020cited by this paper
• SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs

  2020influential reference
• Remdesivir, la esperanza antiviral frente al SARS-CoV-2

  2020cited by this paper
• Neuropilin-1 is a host factor for SARS-CoV-2 infection

  2020influential reference
• The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

  2020cited by this paper
• SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists

  2020influential reference
• New (re)Purpose for an old drug: purinergic receptor blockade may extinguish the COVID-19 thrombo-inflammatory firestorm.

  2020cited by this paper
• Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID‐19

  2020cited by this paper
• Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention

  2020cited by this paper
• Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals

  2020cited by this paper
• Genomewide Association Study of Severe Covid-19 with Respiratory Failure

  2020cited by this paper
• Can mesenchymal stem cell therapy be the interim management of COVID-19?

  2020cited by this paper
• Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases

  2020cited by this paper
• Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

  2020cited by this paper
• Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins

  2020cited by this paper
• Inhibition of SARS–CoV-2 by type I and type III interferons

  2020cited by this paper
• Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

  2020cited by this paper
• Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

  2020cited by this paper
• Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease 2019

  2020cited by this paper
• Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice

  2020cited by this paper
• High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects

  2020cited by this paper
• Lessons for COVID-19 Immunity from Other Coronavirus Infections

  2020cited by this paper
• N-acetylcysteine as a potential treatment for novel coronavirus disease 2019

  2020cited by this paper
• FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy

  2020cited by this paper
• SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

  2020cited by this paper
• Comprehensive mapping of immune perturbations associated with severe COVID-19

  2020cited by this paper
• Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

  2020cited by this paper
• SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2

  2020influential reference
• Targeting TMPRSS2 in SARS-CoV-2 Infection

  2020cited by this paper
• Pharmaco-Immunomodulatory Therapy in COVID-19

  2020cited by this paper
• The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future

  2020cited by this paper
• S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit

  2020cited by this paper
• SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

  2020cited by this paper
• Activation and evasion of type I interferon responses by SARS-CoV-2

  2020influential reference
• Interplay between SARS-CoV-2 and the type I interferon response

  2020cited by this paper
• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling

  2020cited by this paper
• Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects

  2020cited by this paper
• A distinct innate immune signature marks progression from mild to severe COVID-19

  2020influential reference
• DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist

  2020influential reference
• Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions

  2020cited by this paper
• Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies

  2020cited by this paper
• Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

  2020cited by this paper
• Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.

  2020cited by this paper
• What we have to know about corticosteroids use during Sars-Cov-2 infection

  2020cited by this paper
• SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

  2020cited by this paper
• Antibody Responses to SARS-CoV-2: Let’s Stick to Known Knowns

  2020cited by this paper
• Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

  2020cited by this paper

• Plant-derived strategies to fight against severe acute respiratory syndrome coronavirus 2.

  2023cites this paper
• Dynamics of the content of immunoglobulin G to severe acute respiratory syndrome-2 in convalescents who have had a new coronavirus infection

  2023cites this paper
• Prospects of Coffee Leaf against SARS-CoV-2 Infection

  2022cites this paper
• The role of SARS-CoV-2 accessory proteins in immune evasion

  2022cites this paper
• Post acute CoViD-19 syndrome (PACS) - Long CoViD

  2022cites this paper
• Innate Immune Responses by Respiratory Viruses, Including Rhinovirus, During Asthma Exacerbation

  2022cites this paper
• The role of SARS-CoV-2 accessory proteins in immune evasion Biomedicine & Pharmacotherapy

  2022cites this paper
• Immune Cells Profiles In The Peripheral Blood Of Patients With Moderate To Severe COVID-19 And Healthy Subjects With and Without Vaccination With The Pfizer-BioNTech mRNA Vaccine

  2022cites this paper